162. Pemphigoid Clinical trials / Disease details
Clinical trials : 90 / Drugs : 122 - (DrugBank : 47) / Drug target genes : 34 - Drug target pathways : 144
Showing 1 to 4 of 4 diseases
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2021-003087-27-BG (EUCTR) | 19/05/2022 | 07/03/2022 | A study to assess the efficacy and safety of a subcutaneous formulation of efgartigimod PH20 in adults with bullous pemphigoid. A study to assess the efficacy and safety of a subcutaneous formulation of efgartigimod PH20 in adul ... | A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group Study to Investigate the Efficacy and Safety of Efgartigimod PH20 SC in Adult Participants With Bullous Pemphigoid - A phase 2/3 study of efgartigimod PH20 SC in adult participants with bullous pemphigoid A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group Study to Investigate the ... | Bullous Pemphigoid MedDRA version: 21.1;Level: LLT;Classification code 10006567;Term: Bullous pemphigoid;System Organ Class: 100000004858;Therapeutic area: Diseases [C] - Immune System Diseases [C20] Bullous Pemphigoid MedDRA version: 21.1;Level: LLT;Classification code 10006567;Term: Bullous pemphi ... | Product Name: Efgartigimod PH20 SC INN or Proposed INN: EFGARTIGIMOD ALFA | argenx BV | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 160 | Phase 2;Phase 3 | Serbia;United States;Czechia;Slovakia;Greece;Spain;Ukraine;Russian Federation;Israel;United Kingdom;Italy;France;Hungary;Poland;Croatia;Romania;Australia;Bulgaria;Germany;Latvia;Netherlands;China;Japan Serbia;United States;Czechia;Slovakia;Greece;Spain;Ukraine;Russian Federation;Israel;United Kingdom; ... | ||
| 2 | EUCTR2021-003087-27-HR (EUCTR) | 29/04/2022 | 16/05/2022 | A study to assess the efficacy and safety of a subcutaneous formulation of efgartigimod PH20 in adults with bullous pemphigoid. A study to assess the efficacy and safety of a subcutaneous formulation of efgartigimod PH20 in adul ... | A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group Study to Investigate the Efficacy and Safety of Efgartigimod PH20 SC in Adult Participants With Bullous Pemphigoid - A phase 2/3 study of efgartigimod PH20 SC in adult participants with bullous pemphigoid A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group Study to Investigate the ... | Bullous Pemphigoid MedDRA version: 21.1;Level: LLT;Classification code 10006567;Term: Bullous pemphigoid;System Organ Class: 100000004858;Therapeutic area: Diseases [C] - Immune System Diseases [C20] Bullous Pemphigoid MedDRA version: 21.1;Level: LLT;Classification code 10006567;Term: Bullous pemphi ... | Product Name: Efgartigimod PH20 SC INN or Proposed INN: EFGARTIGIMOD ALFA | argenx BV | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 160 | Phase 2;Phase 3 | Germany;China;Japan;Australia;Bulgaria;Serbia;United States;Greece;Spain;Ukraine;Russian Federation;Israel;United Kingdom;Italy;France;Hungary;Poland;Croatia Germany;China;Japan;Australia;Bulgaria;Serbia;United States;Greece;Spain;Ukraine;Russian Federation; ... | ||
| 3 | EUCTR2021-003087-27-ES (EUCTR) | 13/04/2022 | 24/02/2022 | A study to assess the efficacy and safety of a subcutaneous formulation of efgartigimod PH20 in adults with bullous pemphigoid. A study to assess the efficacy and safety of a subcutaneous formulation of efgartigimod PH20 in adul ... | A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group Study to Investigate the Efficacy and Safety of Efgartigimod PH20 SC in Adult Participants With Bullous Pemphigoid - A phase 2/3 study of efgartigimod PH20 SC in adult participants with bullous pemphigoid A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group Study to Investigate the ... | Bullous Pemphigoid MedDRA version: 21.1;Level: LLT;Classification code 10006567;Term: Bullous pemphigoid;System Organ Class: 100000004858;Therapeutic area: Diseases [C] - Immune System Diseases [C20] Bullous Pemphigoid MedDRA version: 21.1;Level: LLT;Classification code 10006567;Term: Bullous pemphi ... | Product Name: Efgartigimod PH20 SC INN or Proposed INN: EFGARTIGIMOD ALFA | argenx BV | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 160 | Phase 2;Phase 3 | United States;Serbia;Greece;Spain;Ukraine;Russian Federation;Israel;United Kingdom;Italy;France;Hungary;Poland;Croatia;Australia;Bulgaria;Germany;China;Japan United States;Serbia;Greece;Spain;Ukraine;Russian Federation;Israel;United Kingdom;Italy;France;Hung ... | ||
| 4 | EUCTR2021-003087-27-HU (EUCTR) | 29/03/2022 | 09/02/2022 | A study to assess the efficacy and safety of a subcutaneous formulation of efgartigimod PH20 in adults with bullous pemphigoid. A study to assess the efficacy and safety of a subcutaneous formulation of efgartigimod PH20 in adul ... | A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group Study to Investigate the Efficacy and Safety of Efgartigimod PH20 SC in Adult Participants With Bullous Pemphigoid - A phase 2/3 study of efgartigimod PH20 SC in adult participants with bullous pemphigoid A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group Study to Investigate the ... | Bullous Pemphigoid MedDRA version: 21.1;Level: LLT;Classification code 10006567;Term: Bullous pemphigoid;System Organ Class: 100000004858;Therapeutic area: Diseases [C] - Immune System Diseases [C20] Bullous Pemphigoid MedDRA version: 21.1;Level: LLT;Classification code 10006567;Term: Bullous pemphi ... | Product Name: Efgartigimod PH20 SC INN or Proposed INN: EFGARTIGIMOD ALFA | argenx BV | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 160 | Phase 2;Phase 3 | United States;Serbia;Greece;Spain;Ukraine;Israel;Russian Federation;United Kingdom;Italy;France;Hungary;Poland;Croatia;Australia;Bulgaria;Germany;China;Japan United States;Serbia;Greece;Spain;Ukraine;Israel;Russian Federation;United Kingdom;Italy;France;Hung ... |